Efficacy and Safety of Dapagliflozin in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction by Baseline Glycaemic Status (DELIVER): a Subgroup Analysis from an International, Multicentre, Double-blind, Randomised, Placebo-controlled Trial
Lancet Diabetes Endocrinol. 2022;10:869–881 DOI: 10.1016/S2213-8587(22)00308-4
Dapagliflozin was shown to be highly efficacious in patients with HFmrEF and HFpEF in the DELIVER trial. However, whether the benefits of dapagliflozin are observed across glycaemia categories has not been previously reported.
In a pre-specified subgroup analysis of DELIVER, there was a stepwise increase in HF outcomes across the three glycaemia categories of normoglycaemia, prediabetes and T2D. Dapagliflozin reduced the composite primary outcome of time from randomisation to first worsening HF events or CV mortality in the three glycaemia subgroups, without heterogeneity, as well as across the entire range of baseline HbA1c values.
The lack of any effect modification by baseline glycaemia adds to the growing evidence that the HF benefits of dapagliflozin are independent of glycaemic status.
Keywords:
